Lexeo Therapeutics’ (NASDAQ:LXEO – Get Free Report) lock-up period is set to expire on Wednesday, May 1st. Lexeo Therapeutics had issued 9,090,910 shares in its initial public offering on November 3rd. The total size of the offering was $100,000,010 based on an initial share price of $11.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the end of the lock-up period.
Lexeo Therapeutics Stock Down 2.7 %
Shares of LXEO opened at $12.16 on Friday. Lexeo Therapeutics has a 12-month low of $9.00 and a 12-month high of $22.33. The stock has a 50-day moving average price of $14.37. The company has a quick ratio of 7.21, a current ratio of 7.21 and a debt-to-equity ratio of 0.01.
Lexeo Therapeutics (NASDAQ:LXEO – Get Free Report) last released its quarterly earnings results on Monday, March 11th. The company reported ($0.86) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.15). As a group, analysts expect that Lexeo Therapeutics will post -3.03 EPS for the current fiscal year.
Institutional Investors Weigh In On Lexeo Therapeutics
Lexeo Therapeutics Company Profile
Lexeo Therapeutics, Inc operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations.
Further Reading
- Five stocks we like better than Lexeo Therapeutics
- How to Use the MarketBeat Excel Dividend Calculator
- Hasbro’s Management Made All the Right Calls This Quarter
- Health Care Stocks Explained: Why You Might Want to Invest
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Power Surge: Utilities Sector’s Resilience Shines
Receive News & Ratings for Lexeo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexeo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.